Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lenti in red: progress in gene therapy for human hemoglobinopathies
Christof von Kalle, Christopher Baum, David A. Williams
Christof von Kalle, Christopher Baum, David A. Williams
View: Text | PDF
Commentary

Lenti in red: progress in gene therapy for human hemoglobinopathies

  • Text
  • PDF
Abstract

Hemoglobinopathies are caused by abnormal structure or synthesis of hemoglobin chains and represent serious monogenic disorders. A new study demonstrates that lentiviral vectors can express clinically relevant levels of human transgenic β-globin in red cells of xenografted mice. While some safety concerns must be addressed, this study is an important step toward potential clinical trials of gene therapy for hemoglobinopathies.

Authors

Christof von Kalle, Christopher Baum, David A. Williams

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Distribution of retrovirus integration into the cellular genome. Lenti- ...
Distribution of retrovirus integration into the cellular genome. Lenti- and other retrovirus vector integration frequently occurs in the vicinity of expressed genes. Integration in intergenic locations, especially at distances of more than 100 kbp’s away from any known gene (I), are least likely to affect the transcription of known genes. MLV-derived vectors appear to have a preference for integrating close to the start of transcription (II), a location especially likely to alter the expression of adjacent endogenous genes. Lentivirus vectors appear to more frequently integrate within the gene (III), a location less likely to affect genetic regulation but potentially more likely to cause disruptions of the mRNA transcript of the endogenous gene.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts